Denca designs control system for pharma facility

Published: 3-Mar-2011
Manufacturing Finance Pharmaceutical

Project in Liverpool worth £500,000

UK-based automation and control systems specialist Denca Controls has been commissioned by a UK producer of pharmaceuticals and biotechnology to supply control systems for its new manufacturing facility in Liverpool in a project worth £500,000.

The new plant is being built to meet demand for the pharmaceutical firm’s dialysis substitute, which frees patients from the need to be connected to a dialysis machine for 8 hours at a time, instead enabling blood to be cleaned from the convenience of a portable bag.

Denca, based in Widnes, Cheshire has used its expertise to develop process diagrams, design and manufacture control panels, as well as provide software, programming, installation and commissioning. In total, five Siemens S7300 PLCs will be networked with MP 277 touchscreen HMIs, a Profibus Remote IO and communication.

John Talbot, sales and marketing director at Denca, said: ‘It’s not often in our line of work that you are given the opportunity to help, in however small a way, to improve lives. In this case, it’s hugely rewarding to know that, through the implementation of control systems for this groundbreaking new product, we would ultimately be helping the company to provide patients with a better control system to make their day to day lives a little easier.’

Denca works across a spectrum of industry sectors including automotive, chemical, food and beverage, healthcare and utilities. It provides process control solutions based on custom-designed, fully integrated PLC and HMI software for both mechanical and electrical operations as well as UKAS-traceable calibration and certification services.

See more

You may also like

Manufacturing

Denca is under control at SAFC plant in Scotland

Read more
Will supply full control system for IPB2 facility at Irvine

Trending Articles

  1. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  2. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  3. Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma Executive with over 20 years of management experience to lead pharmaceutical packaging and delivery systems company
  4. Abzena and Mabqi announce strategic partnership to offer integrated discovery through development solution This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution

You may also like

Manufacturing

Denca is under control at SAFC plant in Scotland

Will supply full control system for IPB2 facility at Irvine
Manufacturing

Pioneering Peptide-Builder debuts at UEA

Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich
Finance

hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline

hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and oncology, bolstering its 2026 orderbook and highlighting the growing cross-selling benefits across the Group
Manufacturing

Moderna invests $140m to onshore drug product manufacturing and complete US end-to-end mRNA network

Moderna is expanding its Norwood, Massachusetts site to bring drug product manufacturing in-house, creating hundreds of biomanufacturing jobs and establishing full domestic, end-to-end production for its mRNA vaccines and therapeutics by 2027
Manufacturing

GEA to showcase Rockwell Automation-Compatible GEA kytero 2000 Single-Use Separator at Automation Fair 2025

As a gold-level OEM member of the Rockwell PartnerNetwork™, GEA is strengthening its collaboration with Rockwell by offering full compatibility between the kytero® 2000 and Rockwell’s latest hardware and software suite
Manufacturing

SU Puresonic ultrasonic sensor ensures precise hygienic flow measurement

Innovative design meets the highest standards in food, pharma, and water treatment
Finance

Sofinnova Partners closes €650m ($750m) Capital XI fund to boost early-stage biotech investment across Europe and the US

Sofinnova Partners has closed its flagship Capital XI fund at €650m, surpassing its target. The Paris-based firm will use the fund to advance early-stage biotech and medtech companies in Europe and North America
Subscribe now